Full Text
The Full Text of this article is available as a PDF (91.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., Chopin D., Thiery J. P., Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999 Sep;23(1):18–20. doi: 10.1038/12615. [DOI] [PubMed] [Google Scholar]
- Fitzsimmons S. A., Workman P., Grever M., Paull K., Camalier R., Lewis A. D. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst. 1996 Mar 6;88(5):259–269. doi: 10.1093/jnci/88.5.259. [DOI] [PubMed] [Google Scholar]
- Garrett M. D., Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer. 1999 Dec;35(14):2010–2030. doi: 10.1016/s0959-8049(99)00280-4. [DOI] [PubMed] [Google Scholar]
- Nelson P. S., Clegg N., Eroglu B., Hawkins V., Bumgarner R., Smith T., Hood L. The prostate expression database (PEDB): status and enhancements in 2000. Nucleic Acids Res. 2000 Jan 1;28(1):212–213. doi: 10.1093/nar/28.1.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thiery J. P., Chopin D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev. 1999;18(1):31–42. doi: 10.1023/a:1006256219004. [DOI] [PubMed] [Google Scholar]